Search results for: Multi-Indication Medicines
Filter search results
Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?
1 June 2019
Cada vez más, los avances científicos desarrollan nuevas medicinas que permiten mejoras en la supervivencia y calidad de vida para diversas indicaciones terapéuticas. La fijación de precios en función de…
Personalised Medicine: Is it an Oil-Rush or Oil-Spill?
3 February 2020, 12:00am
…is accompanied by an awareness of increased complexity in biologic knowledge. This increased biologic information has highlighted the general difficulty associated with personalized medicine. Generally, complex diseases are associated multiple…
Pricing in Emerging Markets: Income, Competition and Procurement
16 August 2011
Most patients in middle and low income countries (MLICs) lack insurance coverage and so pay out of pocket for prescription medicines; pricing commensurate with income thus becomes critical to access…
OHE in the Spotlight: Summer 2011
22 September 2011
…and Processes Value-based pricing (VBP), due to be implemented in the UK for newly marketed medicines as from 2014, remains a key focus of OHE activities. In June, Jon Sussex’s…
Our Contributions to the Economics of Personalised Medicine
7 March 2018
…Pharmacogenetics and Stratified Medicine Network. The Office of Health Economics has made a number of important contributions to the understanding of the economics of stratified/precision/personalised medicines. We have contributed…
We Asked, You Answered: Reflections on the First Round of MVAC Feedback
16 May 2019
…some of the main points raised by disease advocacy and access to medicines civil society groups in particular, and how they have influenced our thinking (though of course, we’ll elaborate…
Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking
15 September 2021
…market. Despite H.R. 3’s unprecedented impact on the world’s largest pharmaceutical market, the CBO model projected that only 8 fewer new medicines (as measured by the number of New Molecular…
OHE Innovation Policy Prize
18 May 2022
…delivers for each and every one of us. The record-breaking development of multiple COVID-19 vaccines, potential curative gene therapies for spinal muscular atrophy, or even the antibiotics which enables medicine…
What is the future of health economics?
1 May 2023
…the study of health systems and improvement. Given the multi-faceted determinants of human health – such as education, employment, and housing – there is a widespread appreciation for the value…